Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
Zhuoya Deng, Yuying Tian, Jianxun Song, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 82

Showing 51-75 of 82 citing articles:

Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology
Eden Mariam Jacob, Jiaoti Huang, Mingqiang Chen
Precision Clinical Medicine (2024) Vol. 7, Iss. 3
Open Access | Times Cited: 1
Current mRNA-based vaccine strategies for glioma treatment
Mengqian Mao, Wanchun Yang, Xuefeng Zhang
Critical Reviews in Oncology/Hematology (2024) Vol. 202, pp. 104459-104459
Closed Access | Times Cited: 1
Mechanisms of resistance to immunotherapy
Bernadette Blauensteiner, Theresa Lentner, Verónica Moreno‐Viedma
Elsevier eBooks (2024), pp. 1-33
Closed Access | Times Cited: 1
Recent Progress in Cancer Vaccines and Nanovaccines
Kishwor Poudel, Tulasi Vithiananthan, Jong Oh Kim, et al.
Biomaterials (2024) Vol. 314, pp. 122856-122856
Closed Access | Times Cited: 1
Effective Synthesis of mRNA during In Vitro Transcription with Fewer Impurities Produced
Wei He, Qi Geng, G. J. Ji, et al.
Molecules (2024) Vol. 29, Iss. 19, pp. 4713-4713
Open Access | Times Cited: 1
mRNA—From COVID-19 Treatment to Cancer Immunotherapy
W. Kŕause
Biomedicines (2023) Vol. 11, Iss. 2, pp. 308-308
Open Access | Times Cited: 4
Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development
Fan Wang
Clinical & Translational Oncology (2023) Vol. 25, Iss. 7, pp. 2204-2223
Open Access | Times Cited: 4
Delivery of Immunostimulatory Cargos in Nanocarriers Enhances Anti-Tumoral Nanovaccine Efficacy
Jenny Schunke, Volker Mailänder, Katharina Landfester, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12174-12174
Open Access | Times Cited: 4
Breaking Barriers: A Future Perspective on Glioblastoma Therapy with mRNA-Based Immunotherapies and Oncolytic Viruses
Alexandro Guterres, Paulo Niemeyer Filho, Vivaldo Moura‐Neto
Vaccines (2024) Vol. 12, Iss. 1, pp. 61-61
Open Access | Times Cited: 1
mRNA vaccines in gastric cancer: How close are we?
José Darío Portillo‐Miño, David Bettin-Gonzalez, Franco Andrés Montenegro Coral
Vacunas (English Edition) (2024) Vol. 25, Iss. 1, pp. 88-96
Closed Access | Times Cited: 1
Next-Generation Vaccines: Nanovaccines in the Fight against SARS-CoV-2 Virus and beyond SARS-CoV-2
Maluta Steven Mufamadi, Mpho Phehello Ngoepe, Ofentse Nobela, et al.
BioMed Research International (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 3
MRI reporter genes in the era of gene transfer
Dan Cohen, Hyla Allouche‐Arnon, Amnon Bar‐Shir
Clinical and Translational Medicine (2022) Vol. 12, Iss. 12
Open Access | Times Cited: 5
mRNA vaccines in gastric cancer: How close are we?
José Darío Portillo‐Miño, David Bettin-Gonzalez, Franco Andrés Montenegro Coral
Vacunas (2023) Vol. 25, Iss. 1, pp. 88-96
Closed Access | Times Cited: 2
Personalized mRNA cancer vaccines with immune checkpoint inhibitors: A promising therapeutic approach in oral cancer patients
S Gheena, Devaraj Ezhilarasan
Oral Oncology (2022) Vol. 137, pp. 106282-106282
Closed Access | Times Cited: 4
Recent treatments to Hepatocellular Carcinoma Cancer(HCC): update and outlook
Letao Lu, Sishuo Ye
Theoretical and Natural Science (2024) Vol. 29, Iss. 1, pp. 25-36
Closed Access
Immunotherapy of Solid Tumors Based on Neoantigen Vaccines
Elahe Aleebrahim‐Dehkordi, Amir Ghaffari Jolfayi, Nima Rezaei
Springer eBooks (2024), pp. 1-19
Closed Access
A new frontier in cancer therapy: The intersection of cancer vaccines and metabolomics
Farah Ayman Sukareh, Ruba Al-Nemi, Peter Karagiannis, et al.
Elsevier eBooks (2024), pp. 143-201
Closed Access
Reaching Outer Space and Enabling the mRNA Revolution: A Critical Role of Partnerships for Successful Drug and Vaccine Development
Anita Seshire, Yukun Duan, Kahina Lang
Handbook of experimental pharmacology (2024)
Closed Access
RNA Therapies in Cancer
Fatemeh Khatami, Setareh Zahedian, Leila Zareian, et al.
(2024), pp. 183-200
Closed Access
Engineered Cellular Immunotherapy for Cancer
Nikita Trivedi
IntechOpen eBooks (2024)
Open Access
Targeting pediatric solid tumors in the new era of RNA therapeutics
Parunya Chaiyawat, Surasak Sangkhathat, Wararat Chiangjong, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 200, pp. 104406-104406
Open Access
Recent Advances in RNA Interference-Based Therapy for Hepatocellular Carcinoma: Emphasis on siRNA
Mohammad S. Alzahrani, Bandar Almutairy, Yusuf S. Althobaiti, et al.
Cell Biochemistry and Biophysics (2024) Vol. 82, Iss. 3, pp. 1947-1964
Closed Access
mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
Alireza Shariati, Pouria Khani, Farzad Nasri, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access
Emergence of Nanoscale Drug Carriers through Supramolecular Self-Assembly of RNA with Calixarene
Ruslan R. Kashapov, Yuliya Razuvayeva, Nadezda E. Kashapova, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7911-7911
Open Access | Times Cited: 1
Aggregatibacter actinomycetemcomitans
Yanyan Fu
(2023)
Open Access

Scroll to top